Armata Pharmaceuticals, Inc. (ARMP) Stock Price & Analysis
Armata Pharmaceuticals, Inc. (ARMP) closed at USD 3.09 on Thursday, October 15, 2026, up 11.15% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.78; the Oct 15, 2026 session ranged USD 2.85–3.16 on volume of 115,670 shares. Market capitalization is $114.89M, with a 52-week range of USD 2.75–16.34 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ARMP.md
Key facts (ARMP)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 17.5 (range 15–20).
- Total return with dividends: 1Y -11.5% vs S&P 500 +18.1%; 5Y -10.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.56, revenue estimate $450K.
Analysts (ARMP)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 17.5 (low 15, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | HC Wainwright & Co. | Reiterated | Buy | $15 |
Total return (dividends reinvested) (ARMP)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -11.5% | -10.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -11.5% | -2.2% |
| Volatility (annualized) | 133.1% | 99.9% |
| Max drawdown | -81.2% (Apr 2026→Oct 2026) | -83.8% (Jan 2022→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 3.09 |
|---|---|
| Change | ▲ 11.15% (up) |
| Previous Close | USD 2.78 |
| Open | USD 2.86 |
| Day Range | USD 2.85 – 3.16 |
| 52-Week Range | USD 2.75 – 16.34 |
| Volume | 115,670 shares |
| Market Cap | $114.89M |
| Exchange | ASE |
Technical Analysis (ARMP)
Nexqual's technical model rates ARMP "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.52 (neutral) |
| vs SMA50 | Below (USD 4.46) |
| MACD | -0.39 (negative) |
Analyst Ratings (ARMP)
Wall Street analysts rate ARMP "Buy" based on 2 analysts, with a mean price target of USD 17.5 (range USD 15–20), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 17.5 |
| High Target | USD 20 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (ARMP)
| Next Earnings Date | 2026-11-11 |
|---|---|
| Revenue Estimate | $450,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.2 vs est -0.45 ▲ beat |
| 2026-03-31 | USD -3.16 vs est -0.38 ▼ miss |
| 2025-12-31 | USD -0.36 vs est -0.19 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.42 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (ARMP)
| Total Revenue | $5.54M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +15.70% |
| Gross Margin | -217.36% |
| Operating Margin | -410.84% |
| Profit Margin | +0.00% |
| Current Ratio | 0.11 |
| Total Cash | $23.95M |
| Total Debt | $313.95M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (ARMP)
Nexqual rates Armata Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $24M cash vs $314M debt |
| Cash Flow | Weak — Operating cash flow -$25M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ARMP)
| Insider Ownership | +67.64% |
|---|---|
| Institutional Ownership | +13.46% |
| Shares Outstanding | 37.18M |
| Float | 11.90M |
| Short % of Float | +8.57% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (ARMP)
Armata Pharmaceuticals, Inc. is led by Deborah L. Birx (age 68), CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Director | Deborah L. Birx (age 68) |
|---|---|
| Chief Financial Officer | David D. House (age 41) |
| Vice President of Operations | Peter Hubbard |
Major Backers & Investors (ARMP)
Notable institutional backers of Armata Pharmaceuticals, Inc. include Madison Asset Management, LLC, Millennium Management, Dauntless Investment Group, LLC , according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Madison Asset Management, LLC | 5.67% |
| Millennium Management | 1.27% |
| Dauntless Investment Group, LLC | 0.55% |
| Fidelity | 0.55% |
| Edgewood Management Llc | 0.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.81% |
| BlackRock | 2.44% |
| Geode Capital | 0.73% |
| State Street | 0.35% |
| Northern Trust | 0.24% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt